All Stories

  1. Structural and evolutionary insights into DAF-12 interactions with transcriptional coactivators in parasitic nematodes
  2. Distinct 2-phenylimidazo[1,2-a]pyridine derivatives that inhibit breast cancer cell proliferation identified as AHR ligands
  3. An integrated structural and functional profiling approach uncovers the mechanisms of PXR binding and activation by pharmaceutical and environmental compounds
  4. Mechanistic Insights of BPA Alternatives on PPARγ Binding and the Consequence on Adipocyte Differentiation
  5. The aryl hydrocarbon receptor: structure, signaling, physiology and pathology
  6. New structural insights into the control of the retinoic acid receptors RAR/RXR by DNA, ligands, and transcriptional coregulators
  7. Targeting pregnane X receptor with a potent agonist-based PROTAC to delay colon cancer relapse
  8. A mechanism for ligand-dependent activation of AHR
  9. A two-in-one expression construct for biophysical and structural studies of the human pregnane X receptor ligand-binding domain, a pharmaceutical and environmental target
  10. An abundant ginger compound furanodienone alleviates gut inflammation via the xenobiotic nuclear receptor PXR in mice
  11. What Structural Biology Tells Us About the Mode of Action and Detection of Toxicants
  12. Structural Insights into the Activation of Human Aryl Hydrocarbon Receptor by the Environmental Contaminant Benzo[a]pyrene and Structurally Related Compounds
  13. Development of new approach methods for the identification and characterization of endocrine metabolic disruptors—a PARC project
  14. 2,4-Di-tert-butylphenol Induces Adipogenesis in Human Mesenchymal Stem Cells by Activating Retinoid X Receptors
  15. Cryo-EM structure of the agonist-bound Hsp90-XAP2-AHR cytosolic complex
  16. Design and in vitro characterization of RXR variants as tools to investigate the biological role of endogenous rexinoids
  17. Structure-Based and Knowledge-Informed Design of B-Raf Inhibitors Devoid of Deleterious PXR Binding
  18. Interspecies Differences in Activation of Peroxisome Proliferator-Activated Receptor γ by Pharmaceutical and Environmental Chemicals
  19. Functional analyses of phosphatidylserine/PI(4)P exchangers with diverse lipid species and membrane contexts reveal unanticipated rules on lipid transfer
  20. Ligands and DNA in the allosteric control of retinoid receptors function
  21. A Comparative Study of Human and Zebrafish Pregnane X Receptor Activities of Pesticides and Steroids Using In Vitro Reporter Gene Assays
  22. Structural Insights into the Interaction of the Intrinsically Disordered Co-activator TIF2 with Retinoic Acid Receptor Heterodimer (RXR/RAR)
  23. How chemical pollutants can become more harmful when combined
  24. Two Novel Cases of Resistance to Thyroid Hormone Due to THRA Mutation
  25. Human and Zebrafish Nuclear Progesterone Receptors Are Differently Activated by Manifold Progestins
  26. High Content Screening Using New U2OS Reporter Cell Models Identifies Harmol Hydrochloride as a Selective and Competitive Antagonist of the Androgen Receptor
  27. Peroxisome proliferator‐activated receptor gamma‐ligand‐binding domain mutations associated with familial partial lipodystrophy type 3 disrupt human trophoblast fusion and fibroblast migration
  28. The GOLIATH Project: Towards an Internationally Harmonised Approach for Testing Metabolism Disrupting Compounds
  29. Structural and Functional Specialization of OSBP-Related Proteins
  30. IDPs and their complexes in GPCR and nuclear receptor signaling
  31. Protein-protein interactions in the regulation of RAR–RXR heterodimers transcriptional activity
  32. Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations
  33. Mechanisms of endocrine disruption through nuclear receptors and related pathways
  34. Interplay of Protein Disorder in Retinoic Acid Receptor Heterodimer and Its Corepressor Regulates Gene Expression
  35. Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity
  36. In Silico Predictions of Endocrine Disruptors Properties
  37. Insights into the activation mechanism of human estrogen-related receptor γ by environmental endocrine disruptors
  38. A revisited version of the apo structure of the ligand-binding domain of the human nuclear receptor retinoic X receptor α
  39. Pathological Interactions Between Mutant Thyroid Hormone Receptors and Corepressors and Their Modulation by a Thyroid Hormone Analogue with Therapeutic Potential
  40. The ancestral retinoic acid receptor was a low-affinity sensor triggering neuronal differentiation
  41. Functional and Structural Study of the Amino Acid Substitution in a Novel Familial Androgen Receptor Mutation (W752G) Responsible for Complete Androgen Insensitivity Syndrome
  42. Structural and functional evidences for the interactions between nuclear hormone receptors and endocrine disruptors at low doses
  43. The Human Mixed Lineage Leukemia 5 (MLL5), a Sequentially and Structurally Divergent SET Domain-Containing Protein with No Intrinsic Catalytic Activity
  44. Fragment-based discovery of a new family of non-peptidic small-molecule cyclophilin inhibitors with potent antiviral activities
  45. L’association fait le poison
  46. Evolutionary diversification of retinoic acid receptor ligand-binding pocket structure by molecular tinkering
  47. Synergistic activation of human pregnane X receptor by binary cocktails of pharmaceutical and environmental compounds
  48. An integrated structure- and system-based framework to identify new targets of metabolites and known drugs
  49. A Novel Mutation in THRA Gene Associated With an Atypical Phenotype of Resistance to Thyroid Hormone
  50. Combining `dry' co-crystallization andin situdiffraction to facilitate ligand screening by X-ray crystallography
  51. Phosphatidylserine transport by ORP/Osh proteins is driven by phosphatidylinositol 4-phosphate
  52. Reporter cell lines to evaluate the selectivity of chemicals for human and zebrafish estrogen and peroxysome proliferator activated γ receptors
  53. Reporter Cell Lines for the Characterization of the Interactions between Human Nuclear Receptors and Endocrine Disruptors
  54. An Unexpected Mode Of Binding Defines BMS948 as A Full Retinoic Acid Receptor β (RARβ, NR1B2) Selective Agonist
  55. Structural and Functional Profiling of Environmental Ligands for Estrogen Receptors
  56. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice
  57. A Mollusk Retinoic Acid Receptor (RAR) Ortholog Sheds Light on the Evolution of Ligand Binding
  58. Selectivity of natural, synthetic and environmental estrogens for zebrafish estrogen receptors
  59. Estrogen‐related receptor γ is an in vivo receptor of bisphenol A
  60. Nuclear Receptor Profiling of Bisphenol-A and Its Halogenated Analogues
  61. Retinoic Acid Receptors: Structural Basis for Coregulator Interaction and Exchange
  62. Diosgenin relieves goiter via the inhibition of thyrocyte proliferation in a mouse model of Graves' disease
  63. Dimerization of Nuclear Receptors
  64. Vers des bisphénols sans effets hormonaux
  65. Structural and mechanistic insights into bisphenols action provide guidelines for risk assessment and discovery of bisphenol A substitutes
  66. SMRTε, a corepressor variant, interacts with a restricted subset of nuclear receptors, including the retinoic acid receptors α and β
  67. Retinoid Receptors and Therapeutic Applications of RAR/RXR Modulators
  68. Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors
  69. Modulation of RXR function through ligand design
  70. Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers
  71. Peroxisome Proliferator-Activated Receptor γ Is a Target for Halogenated Analogs of Bisphenol A
  72. Characterization of Novel Ligands of ERα, Erβ, and PPARγ: The Case of Halogenated Bisphenol A and Their Conjugated Metabolites
  73. Retinoic acid receptor modulators: a perspective on recent advances and promises
  74. Meeting Report: Nuclear Receptors: Transcription Factors and Drug Targets Connecting Basic Research with Translational Medicine
  75. A unique secondary-structure switch controls constitutive gene repression by retinoic acid receptor
  76. A structural view of nuclear hormone receptor: endocrine disruptor interactions
  77. Inverse Agonists and Antagonists of Retinoid Receptors
  78. Allosteric Effects Govern Nuclear Receptor Action: DNA Appears as a Player
  79. Structure of the Third Intracellular Loop of the Vasopressin V2 Receptor and Conformational Changes upon Binding to gC1qR
  80. Differential Action on Coregulator Interaction Defines Inverse Retinoid Agonists and Neutral Antagonists
  81. Modulating Retinoid X Receptor with a Series of (E)-3-[4-Hydroxy-3-(3-alkoxy-5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)phenyl]acrylic Acids and Their 4-Alkoxy Isomers
  82. Pyrazine Arotinoids with Inverse Agonist Activities on the Retinoid and Rexinoid Receptors
  83. Activation of RXR–PPAR heterodimers by organotin environmental endocrine disruptors
  84. Nuclear receptor ligand-binding domains: reduction of helix H12 dynamics to favour crystallization
  85. N-1H-Benzimidazol-5-ylbenzenesulfonamide derivatives as potent hPXR agonists
  86. Modulators of the structural dynamics of the retinoid X receptor to reveal receptor function
  87. Design of selective nuclear receptor modulators: RAR and RXR as a case study
  88. Discovery of a Highly Active Ligand of Human Pregnane X Receptor: A Case Study from Pharmacophore Modeling and Virtual Screening to “In Vivo” Biological Activity
  89. Androgen and estrogen receptors: Potential of crystallography in the fight against cancer
  90. Glutamic Acid 709 Substitutions Highlight the Importance of the Interaction between Androgen Receptor Helices H3 and H12 for Androgen and Antiandrogen Actions
  91. Characterization of the Interaction between Retinoic Acid Receptor/Retinoid X Receptor (RAR/RXR) Heterodimers and Transcriptional Coactivators through Structural and Fluorescence Anisotropy Studies
  92. Monitoring ligand‐mediated nuclear receptor–coregulator interactions by noncovalent mass spectrometry
  93. A new mutation of the androgen receptor, P817A, causing partial androgen insensitivity syndrome: in vitro and structural analysis
  94. Purification and crystallization of the heterodimeric complex of RARβ and RXRα ligand-binding domains in the active conformation
  95. Separation of Retinoid X Receptor Homo- and Heterodimerization Functions
  96. Mutation of the Androgen Receptor at Amino Acid 708 (Gly→Ala) Abolishes Partial Agonist Activity of Steroidal Antiandrogens
  97. Pathophysiology of Androgen Insensitivity Syndromes: Molecular and Structural Approaches of Natural and Engineered Androgen Receptor Mutations at Amino Acid 743
  98. RAR–RXR Selectivity and Biological Activity of New Retinoic Acid Analogues with Heterocyclic or Polycyclic Aromatic Systems
  99. Structural and Functional Evidence for Ligand-Independent Transcriptional Activation by the Estrogen-Related Receptor 3
  100. Nuclear receptor ligand-binding domains: three-dimensional structures, molecular interactions and pharmacological implications
  101. Heterodimeric Complex of RAR and RXR Nuclear Receptor Ligand-Binding Domains: Purification, Crystallization, and Preliminary X-Ray Diffraction Analysis
  102. Ligand- and DNA-induced dissociation of RXR tetramers
  103. Exploring hydrophobic sites in proteins with xenon or krypton
  104. A mutation mimicking ligand-induced conformational change yields a constitutive RXR that senses allosteric effects in heterodimers
  105. Erratum: A canonical structure for the ligand-binding domain of nuclear receptors
  106. Purification, Functional Characterization, and Crystallization of the Ligand Binding Domain of the Retinoid X Receptor
  107. Synthesis of a biospecific adsorbent for the purification of the three human retinoic acid receptors by affinity chromatography